SCNI
Scinai Immunotherapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$1.56
−3.70%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.60
From 52W high−90.43%
Volume211356.00
Market cap$1.10M
P/E (TTM)—
P/S (TTM)0.7x
Div yield—
Key dataSep 18, 2026
Open
$1.60
From 52W high
−90.43%
Volume
211356.00
Market cap
$1.10M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
P/E (TTM)
—
RSI (14)
38.8
MomentumView details →
1D Return
−3.70%
YTD Return
−77.39%
SummaryUpdated Jun 1, 2026
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is a development-stage biopharmaceutical company founded in 2003 and headquartered in Jerusalem, Israel. Originally incorporated as BiondVax Pharmaceuticals Ltd., the company rebranded to its current name in September 2023. Scinai went public in 2015 and focuses on developing innovative therapeutic solutions for infectious diseases, autoimmune conditions, and other medical conditions. The company operates through two primary business segments: research and development of proprietary nanobody therapeutics, and contract development and manufacturing organization (CDMO) services for other biotechnology companies.
Similar companies
Latest newsMore news →